Showing 4951-4960 of 5554 results for "".
- Saudi Arabia Welcomes Scalisi Skin Carehttps://practicaldermatology.com/news/saudi-arabia-welcomes-scalisi-skin-care/2457799/Select doctors’ offices and medical clinics across Saudi Arabia now carry the Scalisi collection. This adds to their existing distribution in spas and medispas in the US, Wynn and Encore Resorts in both Las Vegas, and Macau, China, and online on QVC.com, Amazon.com, and
- Marriage May Reduce Risk of Dying from Melanomahttps://practicaldermatology.com/news/marriage-may-reduce-risk-dying-from-melanoma/2457797/Married folks are more likely to spot a melanoma early, compared with individuals who were never married, divorced or widowed, a new study shows. Researchers tracked data from more tha
- GlobalData: Sun Pharma's Ilumya To Face Strong Competition in the US markethttps://practicaldermatology.com/news/globaldata-sun-pharmas-ilumya-will-face-strong-competition-in-the-us-market/2457816/It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from
- With New Team, Revance Readies for Launch of their Botox Competitorhttps://practicaldermatology.com/news/with-new-team-revance-readies-for-launch-of-their-botox-competitor/2457819/With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launch of for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar lines.
- Escalier Biosciences Closes Financing, Focuses on Psoriasishttps://practicaldermatology.com/news/escalier/2457821/Escalier Biosciences BV, a privately held biopharmaceutical company, this month closed $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventures and BioGeneration Ventures (BGV) completing the round. Escalier is developing both topic
- Novartis' Xolair Recommended in New Global Chronic Urticaria Guidelinehttps://practicaldermatology.com/news/novartis-xolair-recommended-in-new-global-chronic-urticaria-guideline/2457849/A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines. Xolair is the only licensed treatment option for CSU, a type of CU, for pat
- Botox Biosimilar in the Workshttps://practicaldermatology.com/news/botox-biosimilar-in-the-works/2457853/Mylan N.V. and Revance Therapeutics, Inc. are partnering to develop a biosimilar to BOTOX® (onabotulinumtoxinA). "We have reviewed the work done to date by Revance and we are extremely excited and confident
- Early Botox Improves Final Appearance in 'Split-Scar' Studyhttps://practicaldermatology.com/news/early-botox-treatment-improves-final-appearance-in-split-scar-study/2457856/Early injections of botulinum toxin A can improve the final appearance of surgical scars, according to a study in the March issue of Plastic
- Mandy Moore, Garnier Team Up for Beauty Product Recyclinghttps://practicaldermatology.com/news/mandy-moore-garnier-team-up-for-beauty-product-recycling/2457854/Nearly half of Americans don’t recycle their beauty and personal care products, which is why they account for a significant amount of landfill waste, and This Is Us star Mandy Moore, #GarnierGirl and brand ambassador, is teaming up with Garnier and DoSomething.org to kick off the seco
- Burt's Bees Nature-Based Sensitive Skin Regimen Trumps Dermatologist-recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-regimen-trumps-dermatologist-recommended-regimen/2457860/Burt's Bees nature-based sensitive line outperformed a dermatologist-recommended synthetic control regimen in a study of 120 people with clinically diagnosed sensitive skin from rosacea, atopic dermatitis/eczema, or cosmetic intolerance. The nat